NEC and Nagasaki University Team Up for Next-Gen mRNA Vaccine Development

NEC Corporation and Nagasaki University’s DEJIMA Infectious Disease Research Alliance have joined forces in a groundbreaking vaccine development initiative, with up to *750 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI). Their mission? To revolutionize mRNA vaccine technology using “Nanoball,” a cutting-edge innovation designed to enhance stability, boost immune response, and eliminate the need for ultra-low temperature storage.

The project focuses on developing a vaccine for Severe Fever with Thrombocytopenia Syndrome (SFTS), a tick-borne virus posing a rising threat in Japan and East Asia. NEC Oncolmmunity’s AI technology will play a pivotal role in identifying optimal protein candidates, fast-tracking vaccine development.

This breakthrough could be a game-changer for global health, expanding vaccine accessibility in remote and resource-limited regions. CEPI CEO Dr. Richard Hatchett emphasized the importance of preparedness, linking this effort to the "100 Days Mission"—a global initiative to create vaccines for emerging threats within three months. If successful, the Nanoball platform could become a vital tool in combating future pandemics, including the mysterious ‘Disease X.’ With AI-driven precision and next-gen technology, NEC and Nagasaki University are pushing the boundaries of vaccine innovation, paving the way for a safer future.